Olink® to Science
The Olink to Science blog aims to inform, inspire, and support you in all things proteomics. Subscribe to stay updated on the latest proteomics research, ideas, and technological developments.
A broad screen of CSF samples using 11 Olink Target 96 panels analyzed patients with Alzheimer’s Disease with dementia, patients with mild cognitive impairment and who are positive for β-amyloid (MCI Aβ+), and patients with dementia but are negative for β-amyloid (Aβ-). Over a hundred differentially expressed proteins were shown to be dysregulated, and from this data an 8-marker and a 9-marker Olink Focus Panel were designed to discriminate between these three groups with high accuracy (AUC of 0.8-0.99) in an external independent cohort. These marker panels have real diagnostic potential as well as utility in design of clinical trials of drugs targeting various pathological mechanisms of Alzheimer’s Disease.
Alzheimer’s Disease (AD) is a devastating neurodegenerative disorder affecting nearly 50 million worldwide; with only 1-in-4 people diagnosed there is a genuine need for discovery of blood-based biomarkers. A recent paper from a group at Harvard and Massachusetts General Hospital looks at a technical evaluation of reproducibility and biological variation in AD patient samples collected over time.
In the Relapsing-Remitting form of Multiple Sclerosis (RRMS), a single biomarker (soluble neurofilament light chain or sNfL) is identified as a biomarker for inflammatory activity in MS, but is limited in its ability to identify relapses. Through screening several hundred proteins using Olink® technology, three additional protein biomarkers have been identified as an improved relapse-specific signature to monitor disease activity in RRMS patients. Multiple sclerosis (MS) is a chronic autoimmune disease affecting the nervous system (brain and spinal cord) causing the degradation of myelin, the protective insulating layer around nerve fibers. By disrupting the normal signaling to and from the brain, unpredictable symptoms develop: numbness, fatigue and mood changes, all the way up to pain, paralysis and/or blindness. Nearly 1 million people in the United States and up to 2.8 million worldwide live with multiple sclerosis, which is the most common disabling disease of young adults. Current research indicates that a complex set of genetic and environmental factors play a role in its pathogenesis, including low levels of Vitamin D, infection with Epstein-Barr Virus and childhood obesity all implicated.
In a landmark study, 13 pharmaceutical companies in conjunction with researchers from the UK Biobank (UKB) present the largest open-access resource of proteomic data analyzing 1,463 proteins across 54,306 UK Biobank participants. A full 10,248 primary genetic associations were identified, of which 85% were newly discovered. This public scientific resource of unprecedented breadth and depth will uncover biological mechanisms underlying genetic discovery and test hypotheses crucial to the development of improved diagnostics and therapeutics for human disease.
Want to learn more?
Here you will find the latest list of publications that have used Olink’s panels for protein biomarker discovery in the reported studies, or which have reviewed our technology. The publications are grouped according to year of publications.
With our in-house experts, digital tools and technical document library, we support you throughout the whole process of running your project, from study design to data interpretation.
Throughout pharmaceutical development and academic/clinical research, Olink provides actionable insights through protein biomarkers across an extensive range of application areas, covering all aspects of human biology in health and disease.
Protein data points generated
Publications listed on website